Revah joins Genethon as ceo

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Revah brings more than 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.

Immediately prior to joining Genethon, Revah had been chief executive of the oncology start-up Sepal Pharma since 2008. Before that, he was vice president, Drug Discovery, and chief scientific officer of Cerep from 1999 to 2007 and chief executive of its oncology subsidiary.




You may also like

Research & Development

Gene therapy centre to open in France next year

Genethon BioProd to produce 20 clinical batches of gene therapy products a year
Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Pharmaceutical

Moderna named a top employer by Science for eleventh consecutive year

Moderna was recognised for its commitment to continuous innovation and a culture that reflects the values of its employees.
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Manufacturing

Accelerating self-administration and homecare with large-volume prefillable glass syringe

SCHOTT Pharma launches 5.5 ml syringe compatible with autoinjectors to enable comfortable home injections
Manufacturing

Aenova expands sterile fill & finish manufacturing at its Latina site

New line to boost biologics capacity and support a wide range of container formats
Subscribe now